Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19810387 | 0.88 | GABRA1 (0.55) | ALDH1A1LMNATSHRPTGDR2HSD17B10 | |
| SCHEMBL6828111 | 0.86 | ALDH1A1 (0.49) | ALDH1A1LMNATSHRPTGDR2HSD17B10 | |
| SCHEMBL21121055 | 0.85 | ALDH1A1 (0.47) | ALDH1A1LMNATSHRPTGDR2HSD17B10 | |
| SCHEMBL30945155 | 0.84 | ALDH1A1 (0.67) | ALDH1A1LMNATSHRHSD17B10CFTR | |
| SCHEMBL104703 | 0.84 | ALDH1A1 (0.67) | ALDH1A1LMNATSHRHSD17B10CFTR | |
| SCHEMBL987813 | 0.83 | TSHR (0.57) | ALDH1A1LMNATSHRHSD17B10CFTR | |
| SCHEMBL5839700 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNATSHRHSD17B10CFTR | |
| SCHEMBL20377207 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNATSHRHSD17B10CFTR | |
| SCHEMBL1424324 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNATSHRHSD17B10CFTR | |
| SCHEMBL18362458 | 0.82 | ALDH1A1 (0.49) | ALDH1A1LMNATSHRPTGDR2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-11608347-B2 | Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20220213093-A1 | HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3994137-A1 | HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-05-11 | — | — | EP | disclosed |
| CN-114072405-A | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210024546-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-01-28 | — | — | US | disclosed |
| WO-2021001330-A1 | HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-01-07 | — | — | WO | disclosed |
| EP-3737680-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2020-11-18 | — | — | EP | disclosed |
| CN-111566105-A | Octahydropyrido [1, 2-alpha ] pyrazines as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-7622612-B2 | Tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2009-11-24 | — | — | US | disclosed |
| US-7622612-B2 | Tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2009-11-24 | — | — | US | disclosed |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | ACTELION PHARMACEUTICALS,LTD. (CH) | 2008-05-08 | — | — | US | disclosed |
| EP-1784182-A1 | 2-SULFANYL-BENZIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-16 | — | — | EP | disclosed |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| WO-2006021418-A1 | 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | disclosed |
| WO-2004073612-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO. INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213093-A1 | HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, PNLIP, LIPC | ALDH1A1 803/4885LMNA 1007/4885TSHR 2016/4885 |
| US-20210024546-A1 | OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS | PYM1, MAG, MAGI3 | ALDH1A1 556/4885LMNA 2143/4885TSHR 2820/4885 |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | HRH2, HRH1, HRH3 | ALDH1A1 470/4885LMNA 4724/4885TSHR 655/4885 |
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | MGLL, LIPA, LIPC | ALDH1A1 916/4885LMNA 1286/4885TSHR 2474/4885 |
| US-11608347-B2 | Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors | PYM1, MAG, MAGI3 | ALDH1A1 556/4885LMNA 2143/4885TSHR 2820/4885 |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | NFATC1, IL2, CCL2 | ALDH1A1 2078/4885LMNA 4574/4885TSHR 4563/4885 |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | ALDH1A1 785/4885LMNA 1033/4885TSHR 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.